European Commission expands Jemperli (dostarlimab) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer

Rákkutatás · Endometrial cancer

In August 2026, Faeth Therapeutics announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to the combination of sapanisertib and serabelisib (PIKTOR) with paclitaxel for the treatment of patients with advanced or recurrent endometrial cancer whose tumors harbor a PI3K/AKT/mTOR pathway alteration and who have previously been treated with platinum-based chemotherapy and an immune checkpoint inhibitor (ICI).

The DelveInsight report provides a comprehensive analysis of the global pipeline for advanced endometrial cancer therapies, detailing 26+ drugs across clinical development stages, key companies, mechanisms of action, and regulatory pathways. It highlights emerging strategies such as PD‑L1/VEGFR dual inhibition, XPO1 inhibition, and immuno‑cell therapies, and discusses recent FDA designations and trial outcomes, offering stakeholders insights for decision‑making in this evolving therapeutic landscape.

The FDA Fast Track designation accelerates access to a promising combination therapy for a hard‑to‑treat subset of endometrial cancer patients, signaling potential for quicker clinical availability and offering a new therapeutic option where current treatments are limited.

Bizonyítékszint: Állatkísérletes. Állatmodellben vizsgálták.

Eredeti forrás

Kapcsolódó jelek